Novartis teams with India’s Biological E for typhoid vaccine development

Novartis and Indian biopharma Biological E have entered into a development and licensing agreement  to deliver accessible and affordable typhoid and paratyphoid A vaccines to the developing world. Yearly, over 21 million cases and 5 million cases of typhoid and paratyphoid A fever respectively are reported, with many typhoid victims being children younger than two for which there is no …

GSK announces new joint venture in emerging vaccine market – are joint ventures critical?

With GlaxoSmithKline (GSK) recently announcing an agreement to form a joint venture with Indian vaccine company Biological E, this may be a sign that innovative collaborations are becoming more critical for building presence in emerging markets. GSK and Biological E have established a 50/50 joint venture to develop a 6-in-1 vaccine that combines GSK's injectable polio vaccine with Biological E's …